Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Capital Expenditures (2016 - 2026)

Cytosorbents filings provide 15 years of Capital Expenditures readings, the most recent being $108000.0 for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 152.17% to $108000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $164000.0, a 1950.0% increase, with the full-year FY2025 number at $164000.0, up 1950.0% from a year prior.
  • Capital Expenditures hit $108000.0 in Q4 2025 for Cytosorbents, up from $17000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.6 million in Q4 2021 to a low of -$480415.0 in Q2 2022.
  • Median Capital Expenditures over the past 5 years was $50905.0 (2022), compared with a mean of $247964.6.
  • The widest YoY moves for Capital Expenditures: up 2147.6% in 2021, down 629.44% in 2021.
  • Cytosorbents' Capital Expenditures stood at $3.6 million in 2021, then tumbled by 97.82% to $79236.0 in 2022, then increased by 20.52% to $95497.0 in 2023, then plummeted by 316.76% to -$207000.0 in 2024, then soared by 152.17% to $108000.0 in 2025.
  • The last three reported values for Capital Expenditures were $108000.0 (Q4 2025), $17000.0 (Q3 2025), and $36879.0 (Q2 2025) per Business Quant data.